Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor As a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Apr 28

PMID 35480116

Authors

Elahe Minaei

Simon A Mueller

Bruce Ashford

Amarinder Singh Thind

Jenny Mitchell

Jay R Perry

Benjamin Genenger

Jonathan R Clark

Ruta Gupta

Marie Ranson

Affiliations

Soon will be listed here.

Abstract

Cutaneous squamous cell carcinoma (cSCC) of the head and neck region is the second most prevalent skin cancer, with metastases to regional lymph nodes occurring in 2%-5% of cases. To further our understanding of the molecular events characterizing cSCC invasion and metastasis, we conducted targeted cancer progression gene expression and pathway analysis in non-metastasizing (PRI-) and metastasizing primary (PRI+) cSCC tumors of the head and neck region, cognate lymph node metastases (MET), and matched sun-exposed skin (SES). The highest differentially expressed genes in metastatic (MET and PRI+) versus non-metastatic tumors (PRI-) and SES included , , , , , , , and various inflammatory cytokine genes. Pathway enrichment analyses implicated these genes in cellular pathways and functions promoting matrix remodeling, cell survival and migration, and epithelial to mesenchymal transition, which were all significantly activated in metastatic compared to non-metastatic tumors (PRI-) and SES. We validated the overexpression of urokinase plasminogen activator receptor (uPAR, encoded by ) in an extended patient cohort by demonstrating higher uPAR staining intensity in metastasizing tumors. As pathway analyses identified epidermal growth factor (EGF) as a potential upstream regulator of , the effect of EGF on uPAR expression levels and cell motility was functionally validated in human metastatic cSCC cells. In conclusion, we propose that uPAR is an important driver of metastasis in cSCC and represents a potential therapeutic target in this disease.

Citing Articles

Urokinase Plasminogen Activation System Modulation in Transformed Cell Lines.

Culej Bosnjak D, Balent T, Korac P, Antica M, Matulic M Int J Mol Sci. 2025; 26(2).

PMID: 39859388 PMC: 11765620. DOI: 10.3390/ijms26020675.

Molecular and Histopathological Characterization of Metastatic Cutaneous Squamous Cell Carcinomas: A Case-Control Study.

Paganelli A, Zaffonato M, Donati B, Torricelli F, Manicardi V, Lai M Cancers (Basel). 2024; 16(12).

PMID: 38927938 PMC: 11202054. DOI: 10.3390/cancers16122233.

PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro.

Perry J, Genenger B, Thind A, Ashford B, Ranson M Cancers (Basel). 2024; 16(2).

PMID: 38254859 PMC: 10814950. DOI: 10.3390/cancers16020370.

Sex as a Predictor of Response to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.

Yeo N, Genenger B, Aghmesheh M, Thind A, Napaki S, Perry J Cancers (Basel). 2023; 15(20).

PMID: 37894393 PMC: 10605413. DOI: 10.3390/cancers15205026.

Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.

Leth J, Newcombe E, Gronnemose A, Jorgensen J, Qvist K, Clausen A Sci Rep. 2023; 13(1):17248.

PMID: 37821532 PMC: 10567728. DOI: 10.1038/s41598-023-43934-w.

References

Lazo de la Vega L, Bick N, Hu K, Rahrig S, Silva C, Matayoshi S . Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. Mod Pathol. 2020; 33(11):2280-2294. PMC: 7934000. DOI: 10.1038/s41379-020-0571-7. View

Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V . Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer. 2008; 7:85. PMC: 2599898. DOI: 10.1186/1476-4598-7-85. View

Ji A, Rubin A, Thrane K, Jiang S, Reynolds D, Meyers R . Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma. Cell. 2020; 182(2):497-514.e22. PMC: 7391009. DOI: 10.1016/j.cell.2020.05.039. View

Yu G, He Q . ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2015; 12(2):477-9. DOI: 10.1039/c5mb00663e. View

Lu P, Weaver V, Werb Z . The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196(4):395-406. PMC: 3283993. DOI: 10.1083/jcb.201102147. View

Jee B, Lim H, Kwon S, Jo Y, Park M, Lee I . Molecular classification of basal cell carcinoma of skin by gene expression profiling. Mol Carcinog. 2014; 54(12):1605-12. DOI: 10.1002/mc.22233. View

Marschall C, Lengyel E, Nobutoh T, Braungart E, DOUWES K, Simon A . UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol. 1999; 113(1):69-76. DOI: 10.1046/j.1523-1747.1999.00631.x. View

O-Charoenrat P, Rhys-Evans P, Eccles S . Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001; 127(7):813-20. View

Madunic J . The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role. Thromb Haemost. 2018; 118(12):2020-2036. DOI: 10.1055/s-0038-1675399. View

10.

Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi B . Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer. 2017; 17(1):572. PMC: 5574145. DOI: 10.1186/s12885-017-3563-3. View

11.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

12.

Magnussen S, Rikardsen O, Hadler-Olsen E, Uhlin-Hansen L, Steigen S, Svineng G . Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). PLoS One. 2014; 9(7):e101895. PMC: 4084992. DOI: 10.1371/journal.pone.0101895. View

13.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

14.

McCarthy D, Chen Y, Smyth G . Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012; 40(10):4288-97. PMC: 3378882. DOI: 10.1093/nar/gks042. View

15.

Canueto J, Cardenoso E, Garcia J, Santos-Briz A, Castellanos-Martin A, Fernandez-Lopez E . Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol. 2016; 176(5):1279-1287. DOI: 10.1111/bjd.14936. View

16.

Perera E, Gnaneswaran N, Staines C, Win A, Sinclair R . Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review. Australas J Dermatol. 2015; 56(4):258-67. DOI: 10.1111/ajd.12282. View

17.

Shimada T, Nakamura H, Yamashita K, Kawata R, Murakami Y, Fujimoto N . Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin Exp Metastasis. 2001; 18(2):179-88. DOI: 10.1023/a:1006749501682. View

18.

Tincknell G, Piper A, Aghmesheh M, Becker T, Vine K, Brungs D . Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma. Cancers (Basel). 2021; 13(16). PMC: 8393967. DOI: 10.3390/cancers13164097. View

19.

Bhattacharya A, Hamilton A, Furberg H, Pietzak E, Purdue M, Troester M . An approach for normalization and quality control for NanoString RNA expression data. Brief Bioinform. 2020; 22(3). PMC: 8138885. DOI: 10.1093/bib/bbaa163. View

20.

Zilberg C, Lee M, Yu B, Ashford B, Kraitsek S, Ranson M . Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Mod Pathol. 2017; 31(2):275-287. DOI: 10.1038/modpathol.2017.128. View